Journal: Biological & pharmaceutical bulletin

Article Title: Cas9 in Genetically Modified Food Is Unlikely to Cause Food Allergy.

doi: 10.1248/bpb.b16-00542

Figure Lengend Snippet: Fig. 1. Enzymatic Activity of Cas9 Was Confirmed by in Vitro Plasmid Cleavage Assay

Article Snippet: The membranes were blocked in Blocking One (Nacalai Tesque, Kyoto, Japan) and then incubated with diluted Guide-itTM Cas9 Polyclonal Antibody (TaKaRa Bio USA, Mountain View, CA, U.S.A.).

Techniques: Activity Assay, In Vitro, Plasmid Preparation, Cleavage Assay

Journal: Biological & pharmaceutical bulletin

Article Title: Cas9 in Genetically Modified Food Is Unlikely to Cause Food Allergy.

doi: 10.1248/bpb.b16-00542

Figure Lengend Snippet: Fig. 2. Cas9 Was Digested in Simulated Gastric Fluid (SGF) for the Indicated Periods (min)

Article Snippet: The membranes were blocked in Blocking One (Nacalai Tesque, Kyoto, Japan) and then incubated with diluted Guide-itTM Cas9 Polyclonal Antibody (TaKaRa Bio USA, Mountain View, CA, U.S.A.).

Techniques:

Journal: Biological & pharmaceutical bulletin

Article Title: Cas9 in Genetically Modified Food Is Unlikely to Cause Food Allergy.

doi: 10.1248/bpb.b16-00542

Figure Lengend Snippet: Fig. 3. Cas9 Was Digested in Simulated Gastric Fluid for the Indicated Periods (min), Which Were Longer Than Those in Fig. 2

Article Snippet: The membranes were blocked in Blocking One (Nacalai Tesque, Kyoto, Japan) and then incubated with diluted Guide-itTM Cas9 Polyclonal Antibody (TaKaRa Bio USA, Mountain View, CA, U.S.A.).

Techniques:

Journal: Biological & pharmaceutical bulletin

Article Title: Cas9 in Genetically Modified Food Is Unlikely to Cause Food Allergy.

doi: 10.1248/bpb.b16-00542

Figure Lengend Snippet: Fig. 4. Thermal Stability of Cas9 Was Examined

Article Snippet: The membranes were blocked in Blocking One (Nacalai Tesque, Kyoto, Japan) and then incubated with diluted Guide-itTM Cas9 Polyclonal Antibody (TaKaRa Bio USA, Mountain View, CA, U.S.A.).

Techniques:

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Production and Characterization of Cas9 Gesicles

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Assaying Gesicle Size and Concentration

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques: Concentration Assay

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Gesicle Treatment Rapidly Delivers Protein to CHME-5 Microglia

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Schematic of the HIV Long Terminal Repeat and Expected Products after CRISPR/Cas9 Targeting by Gesicles

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques: CRISPR

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Gesicle Treatment Causes Specific Mutation Events at the HIV LTR

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques: Mutagenesis

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Gesicle Treatment Reduces HIV Proviral Activity

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques: Activity Assay

Journal: Molecular Therapy

Article Title: Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus

doi: 10.1016/j.ymthe.2018.10.002

Figure Lengend Snippet: Gesicle Dosage and Viability

Article Snippet: Unless otherwise noted, gesicles were prepared using the Guide-it CRISPR/Cas9 Gesicle Production System (catalog [Cat.] no. 631613; Clontech/Takara, Mountain View, CA, USA) according to the manufacturer’s instructions.

Techniques: